Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST: Bardoxolone Methyl in CTD-PAH
NCT02657356Phase 3Terminated
- Sponsor
- Biogen
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of bardoxolone methyl in pulmonary arterial hypertension (PAH), sponsored by Biogen. Started Oct 2016; status: terminated.
02
Drugs
bardoxolone methyl
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02657356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657356.